Hospital
MH Transylvania Regional Hospital, LLLP
MH Transylvania Regional Hospital, LLLP was paid $5.35M by Medicaid between Feb 2019 and Dec 2024, across 103 billing codes. Its largest line is 99283, emergency room visit (moderate) — 31% of everything it billed.
33Billing provider infoMH TRANSYLVANIA REGIONAL HOSPITAL, LLLP
BREVARD, NC 28712
BREVARD, NC 28712
33aNPI1417432139assigned 09/27/2018
33bProvider typeCritical Access Hospital
28Total paid$5.35M
24GClaims79,197
24DCodes billed103
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in North Carolina
Rank by total paid#5 of 25
Median peer was paid$1.32M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 16,545 | $1.09M | |
| 2020 | 20,791 | $1.21M | |
| 2021 | 17,050 | $1.15M | |
| 2022 | 10,528 | $690K | |
| 2023 | 9,461 | $708K | |
| 2024incomplete | 4,822 | $514K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 8,861 | 7,913 | $1.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 5,306 | 4,565 | $1.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.2% | 504 | 457 | $493K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 1,389 | 1,192 | $443K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.5% | 600 | 524 | $189K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 1,973 | 1,792 | $172K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 2,810 | 2,372 | $133K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 1,924 | 1,687 | $92K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 1,300 | 1,050 | $84K |
| 80053 | Comprehensive metabolic panel | 1.2% | 7,855 | 6,637 | $64K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 1,542 | 1,446 | $59K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 1,134 | 916 | $54K |
91 more codes
| 85027 | <1% | 9,052 | $53K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,054 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 528 | $31K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,139 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 361 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,753 | $25K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 488 | $25K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 287 | $23K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 30 | $19K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 375 | $14K |
| 80061 | Lipid panel | <1% | 846 | $11K |
| 80306 | <1% | 469 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 358 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 200 | $11K |
| 81001 | <1% | 3,452 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 337 | $10K |
| 84484 | <1% | 1,445 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,334 | $8K |
| 83690 | <1% | 1,334 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 78 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 886 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 260 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 861 | $6K |
| 86780 | <1% | 437 | $6K | |
| 83735 | <1% | 1,313 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 222 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 222 | $6K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 584 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,744 | $5K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 750 | $5K |
| 81025 | <1% | 630 | $4K | |
| 96376 | <1% | 87 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 143 | $4K |
| 83880 | <1% | 194 | $4K | |
| 83605 | <1% | 457 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 254 | $3K |
| 84703 | <1% | 361 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 129 | $3K |
| 86703 | <1% | 205 | $3K | |
| 87634 | <1% | 59 | $3K | |
| 86803 | <1% | 163 | $2K | |
| 11721 | <1% | 79 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 155 | $2K |
| 87040 | <1% | 266 | $2K | |
| 85610 | <1% | 520 | $2K | |
| 86850 | <1% | 157 | $2K | |
| 73630 | <1% | 28 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 232 | $2K |
| 87077 | <1% | 197 | $2K | |
| 72100 | <1% | 31 | $1K | |
| 87186 | <1% | 175 | $1K | |
| 84439 | <1% | 141 | $1K | |
| 87340 | <1% | 113 | $1K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 17 | $962.14 |
| 86762 | <1% | 60 | $910.59 | |
| 73110 | <1% | 12 | $890.06 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 176 | $881.15 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 551 | $849.86 |
| 73130 | <1% | 14 | $830.73 | |
| 86787 | <1% | 60 | $799.20 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 18 | $787.09 |
| 73610 | <1% | 17 | $786.57 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 227 | $781.86 |
| 74018 | <1% | 13 | $654.42 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 43 | $620.84 |
| 73030 | <1% | 15 | $572.80 | |
| 11719 | <1% | 26 | $541.82 | |
| 86901 | <1% | 162 | $453.88 | |
| 86900 | <1% | 162 | $453.78 | |
| 85730 | <1% | 98 | $374.82 | |
| 82607 | <1% | 15 | $337.41 | |
| 85379 | <1% | 44 | $312.67 | |
| J3490 | Unclassified drugs | <1% | 812 | $306.20 |
| 84702 | <1% | 32 | $290.00 | |
| 11720 | <1% | 14 | $283.23 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $281.97 |
| Q3014 | Telehealth originating site facility fee | <1% | 36 | $220.01 |
| 82728 | <1% | 12 | $196.02 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 22 | $133.27 |
| 85651 | <1% | 32 | $108.85 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 31 | $101.97 |
| 82950 | <1% | 15 | $77.33 | |
| 86140 | <1% | 14 | $60.93 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 32 | $42.59 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15 | $39.81 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 34 | $33.35 |
| 81003 | <1% | 14 | $23.76 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 23 | $17.84 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 76 | $0.00 |
| 82077 | 0% | 25 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPILON, MICHELE (CEO)
| Provider | Location | Paid |
|---|---|---|
| MH Transylvania Regional Hospital, LLLP | Clyde, NC | $1.59M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.